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Summary
 
The structurally related T cell surface molecules CD28 and CTLA-4 interact with cell surface
ligands CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells (APC) and modulate T cell
antigen recognition. Preliminary reports have suggested that CD80 binds CTLA-4 and CD28
with affinities (
 
K
 
d
 
 values 
 
z
 
12 and 
 
z
 
200 nM, respectively) that are high when compared with
other molecular interactions that contribute to T cell–APC recognition. In the present study,
we use surface plasmon resonance to measure the affinity and kinetics of CD80 binding to
CD28 and CTLA-4. At 37
 
8
 
C, soluble recombinant CD80 bound to CTLA-4 and CD28 with
 
K
 
d
 
 values of 0.42 and 4 
 
m
 
M, respectively. Kinetic analysis indicated that these low affinities
were the result of very fast dissociation rate constants (k
 
off
 
); sCD80 dissociated from CD28 and
CTLA-4 with k
 
off
 
 values of 
 
>
 
1.6 and 
 
>
 
0.43 s
 
2
 
1
 
, respectively. Such rapid binding kinetics have
also been reported for the T cell adhesion molecule CD2 and may be necessary to accommo-
date dynamic T cell–APC contacts and to facilitate scanning of APC for antigen.
 
C
 
D28 (1, 2) and CTLA-4 (3) are structurally related cell
surface molecules, largely restricted to the T cell lin-
eage, which contribute to antigen recognition by T cells
(for reviews see references 4–6). They do so by interacting
with the structurally related ligands CD80 (B7-1, B7; 7, 8)
and CD86 (B7-2, B70; 9–12), which are expressed on
APC. Numerous reports (reviewed in references 4–6) have
shown that, upon ligation, CD28 transmits activation sig-
nals that enhance T cell activation through the TCR. The
role of CTLA-4 is more controversial (13), but recent in
vivo studies (14–16) suggest that, unlike CD28, CTLA-4
ligation inhibits T cell activation, apparently by inhibiting
signaling through the TCR (17).
Antigen recognition by T cells is unusual in that it oc-
curs at the interface between two cells in direct physical
contact, and CD28 is one of several T cell surface mole-
cules that participate in this interaction (18, 19). It is be-
coming evident that T cells are sensitive to quantitative
changes in the molecular interactions that contribute to
T cell antigen recognition, and that quantitative differences
in, for example, binding affinity, kinetics, or surface den-
sity, can lead to very different T cell responses (20–24).
Clearly, our understanding of antigen recognition would
be aided by knowledge of the affinity and binding kinetics
of the individual molecular interactions. Recent studies have
provided affinity and kinetic data on the interactions of the
TCR with peptide–MHC (25) and CD2 with its ligands
CD48 (26) and CD58 (27, 28). In contrast, the interactions
of CD28 and CTLA-4 with their ligands are less well char-
acterized. Estimates have been made of the relative avidity
and kinetics of CD28 and CTLA-4 binding to CD80 and
CD86 (8, 29, 30), but no definitive affinity or kinetic data
are available. A soluble CD80 Ig fusion protein was re-
ported to bind to CD28 with a dissociation constant (
 
K
 
d
 
) of
 
z
 
200 nM (29) and to CTLA-4 with a 
 
K
 
d
 
 of 
 
z
 
12 nM (8),
but there was evidence that this CD80 Ig was not mono-
meric in solution (29). More recent kinetic studies have re-
lied entirely on dimeric Ig fusion proteins (30, 31). Al-
though potentially informative for comparative purposes,
such studies do not provide accurate affinity and kinetic
data of the sort that can be used to develop quantitative
models of Ag recognition by T cells.
In the present study, we undertook to obtain precise es-
timates of the solution affinity and kinetic constants for the
interaction between CD80 and both CD28 and CTLA-4.
Molecules involved in cell–cell recognition can have very
low affinities and fast dissociation rate constants, leading to
technical problems in their measurement (32, 33). Recent
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studies (for reviews see 33, 34) have demonstrated that
surface plasmon resonance (SPR)
 
1
 
, as implemented in the
BIAcore instrument (35), is well suited to analysis of such
interactions. We use SPR to show that CD80 binds CD28
and CTLA-4 with affinities considerably lower than previ-
ously reported, and with very fast kinetics.
 
Materials and Methods
 
Expression of CTLA-4 Ig.
 
The CTLA-4 Ig construct was very
similar to that previously described (8) and was made by PCR, us-
ing as a template a cDNA library prepared from human peripheral
blood acute lymphoblastic leukemia cells (Daenke, S., unpublished
data). The 116 base 5
 
9
 
 primer CTAGCCACTGAAGCTTC-
ACCAATGGGTGTACTGCTCACACAGAGGACGCTGCT-
CAGTCTGGTCCTTGCACTCCTGTTTCCAAGCATGG-
CGAGCATGGCAATGCACGTGGCCCAGCC encoded the
oncostatin M leader (36) and 20 bases of CTLA-4 sequence and
incorporated a HindIII restriction site. The encoded junction be-
tween the oncostatin leader (uppercase) and CTLA-4 (lowercase)
was as follows: SMASMamhva. The 3
 
9
 
 primer ACGGATCC-
TTATCAGAATCTGGGCACGGTTC encoded the CTLA-4
sequence immediately upstream of the transmembrane region fol-
lowed by a splice donor site and a BamHI restriction site. The
amplified product was subcloned into the pIg expression vector
(37) using its BamHI and HindIII restriction sites. pIg incorpo-
rates, downstream of the cloning site, a genomic sequence encod-
ing the constant region of human IgG 
 
g
 
1
 
 heavy chain. After splic-
ing, the encoded junction between CTLA-4 (uppercase) and the
 
g
 
1
 
 heavy chain (lowercase) would be as follows: CPDSDepsksc.
The sequence was confirmed by dideoxy sequencing. Stable high
level expression of CTLA-4 Ig in Chinese hamster ovary (CHO)–
K1 cells was achieved by calcium phosphate cotransfection of the
CTLA-4 Ig encoding plasmid together with the glutamine syn-
thetase–encoding expression vector pEE14, as previously de-
scribed (38–40). Clones expressing high levels of CTLA-4 Ig
(
 
z
 
30–40 mg/L) were identified by inhibition ELISA using a
mAb specific for human IgG (40) and grown up to confluence in
bulk culture before switching to serum-free medium supple-
mented with 2 mM Na butyrate. CTLA-4 Ig was then purified
by affinity chromatography on protein A–sepharose (Pharmacia
Biotech AB, Uppsala, Sweden) followed by size-exclusion chro-
matography on a SUPERDEX S200 HR10/30 column (Pharma-
cia Biotech).
 
Expression and Analysis of sCD80.
 
The soluble CD80 con-
struct was designed to encode the extracellular portion of CD80
up to lysine-209 followed by a carboxy-terminal oligo-histidine
tag for purification (sCD80his). It was made by PCR using
cDNA from MT-2 cells (HTLV-1-transformed human T cells) as
template. The 5
 
9
 
 primer TAGTAGAAGCTTTCCCCATCC-
GCTCAAGCAGGCCACCATGGGCCACACACGGAGG was
complementary to the CD80 leader sequence but added an
HindIII site and inserted, immediately upstream of the initiation
codon, the 25 bases that precede the rat CD4 initiation codon
(41). The 3
 
9
 
 primer TAGTAGTCTAGACTAATGATGATGA-
TGATGATGCTTGGCTGTATTCCAGTTGAAGGT added six
histidine residues and a stop codon after lysine 209, mutated thre-
onine 208 to alanine to remove a potential NH
 
2
 
-linked glycosy-
lation site, and added a XbaI site. The 10 carboxy-terminal amino
acids of sCD80his were thus NTAKHHHHHH. The resulting
PCR fragment was subcloned into the glutamine synthetase expres-
sion vector pEE14 (39) using its XbaI and HindIII restriction sites,
and the sequence was confirmed by dideoxy sequencing. CHO-K1
cells were transfected as described (38, 39) with the sCD80his-
encoding plasmid by calcium phosphate transfection. Clones express-
ing high levels of sCD80his (
 
z
 
40 mg/L) were identified by growth
in the presence of [
 
35
 
S]methionine/[
 
35
 
S]cysteine (TRANS
 
35
 
S-
LABEL; ICN Pharmaceuticals, Costa Mesa, CA), purification of
labeled protein from the culture supernatant using Ni-NTA spin
columns (Qiagen GmbH, Hilden, Federal Republic of Ger-
many), and then SDS-PAGE of the protein followed by autorad-
iography. The best clone was grown up to confluence in bulk
culture before switching to serum-free medium supplemented
with 2 mM Na butyrate. sCD80his was purified by affinity chro-
matography using Ni-NTA resin (Qiagen GmbH) followed by
size-exclusion chromatography on a SUPERDEX S200 HR10/30
column. The extinction coefficient (at 280 nm) of sCD80his was
determined by amino acid analysis to be 1.41 ml.mg
 
2
 
1
 
. The car-
boxy-terminal his tag was cleaved off by incubating 2.5 mg of
sCD80his in 1.5 ml Tris–saline buffer (140 mM NaCl, 10 mM
Tris [pH 7.5]) with 1.2 U of carboxypeptidase A conjugated to
agarose beads (Sigma Chemical, Poole, UK) for 16 h at 30
 
8
 
C
with agitation. Amino acid analysis confirmed that 
 
>
 
90% of the
carboxy-terminal histidine residues (5.4 molecules per sCD80his
molecule), but no other amino acids, were released during this
incubation (data not shown). The carboxypeptidase A was re-
moved by centrifugation and the digested sCD80his (sCD80) was
repurified on a SUPERDEX S200 HR10/30 column (Fig. 1 
 
C
 
).
The proportion of sCD80 that possessed ligand binding activ-
ity was determined as follows. Protein A–sepharose beads (100 
 
m
 
l)
were incubated with 0.4 mg of CTLA-4 Ig or (as a control)
CD22 (d1-3) Ig (42) in 0.33 ml Tris–saline for 1 h at 4
 
8
 
C with
rotation and then washed three times with 1.5 ml Tris–saline.
CTLA-4 Ig or CD22 Ig beads (40 
 
m
 
l) were then added to 20 
 
m
 
l
sCD80 (0.65 
 
m
 
g/
 
m
 
l in Tris–saline) and incubated for 4 h at 4
 
8
 
C
with rotation. The beads were then pelleted and 10 
 
m
 
l of each su-
pernant analyzed by SDS-PAGE, together with 3.3 
 
m
 
l of sCD80
that had not been exposed to beads (Fig. 1 
 
B
 
).
 
SPR Experiments.
 
Binding experiments were performed by
SPR on a BIAcore instrument (35) upgraded with the BIAcore
Upgrade Kit (BIAcore AB, St Albans, UK). All experiments were
performed at 37
 
8
 
C (except where otherwise indicated) using
HBSS buffer (25 mM Hepes [pH 7.4], 150 mM NaCl, 3.4 mM
EDTA, and 0.005% surfactant P20) supplied by BIAcore. CTLA-4
Ig and CD28 Ig were covalently coupled by primary amine
groups to the carboxymethylated dextran matrix on a research
grade CM5 sensor chip (BIAcore) using the Amine Coupling Kit
(BIAcore) as directed (43), with the following modifications. After
an activation step of 15–240 s, CTLA-4 Ig (30 
 
m
 
g/ml in 10 mM
Na acetate [pH 4.7]) or CD28 Ig (15 
 
m
 
g/ml in 10 mM Na ace-
tate [pH 5]) were injected for 7 min. After coupling, CTLA-4
Ig and CD28 Ig were washed with a 3 min injection of NaOH
(5 mM). NaOH (5 mM) was also used to regenerate immobilized
CD28 Ig and CTLA-4 Ig. The anti-human IgG
 
1
 
 mAb R10Z8E9
was used as previously described (44) to immobilize CD28 Ig and
CTLA-4 Ig indirectly to the sensor surface via their Ig fragment.
 
Analysis of Affinity and Kinetic Data.
 
Equilibrium binding analysis
and analysis of the washout or dissociation phase was performed as
previously described (27). Analysis of the injection or association
phase was performed using the BIAevaluation software Version
 
1
 
Abbreviations used in this paper:
 
 CHO, Chinese hamster ovary; FC, flow
cell; 
 
k
 
off
 
, dissociation rate constant; 
 
k
 
on
 
, association rate constant; RU, re-
sponse unit; sCD80his, soluble CD80 with carboxy-terminal oligo-histi-
dine tag; SPR, surface plasmon resonance.  
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2.1 (BIAcore). The k
 
on
 
 was determined by nonlinear curve fitting
of the following equation to the injection phase.
(1)
 
where 
 
R
 
(
 
t
 
) is the response (in response units) at time 
 
t
 
, R
 
eq
 
is the response at equilibrium, and C is the concentration
of injected sCD80. The k
 
off
 
 value used for this fit was ob-
tained by analysis of the washout phase of the same injec-
tion. For the CTLA-4–sCD80 interaction, the k
 
on
 
 was also
estimated using an approach relying entirely on analysis of
the injection phase, as described by Karrlson et al. (43). Af-
ter injection at several different sCD80 concentrations,
Rt () R eq 1 e
kon C koff ) t × + × ( –
– èø
æö
× =
 
plots of dR/dt versus R for each concentration (C) give
straight lines with a slope 
 
2
 
k
 
s
 
 where
(2)
Values for 
 
k
 
on
 
 and 
 
k
 
off
 
 were obtained by a linear fit of a plot
of 
 
k
 
s
 
 versus C (see Fig. 4 
 
E
 
).
 
Results and Discussion
 
Expression and Characterization of Monomeric sCD80.
 
A solu-
ble form of CD80 with a carboxy-terminal oligo-his tag
(sCD80his) was expressed in CHO-K1 cells. Preliminary ex-
periments indicated that the oligo-histidine tag predisposed
towards the formation of multimeric aggregates (van der
Merwe, P.A., and S.J. Davis, unpublished data) and so it
was removed by digestion with carboxypeptidase A (see
Materials and Methods) to yield sCD80. Analysis of sCD80
by reducing SDS-PAGE indicated that it migrated as a
broad band with a size range of M
 
r
 
 35–45,000 (Fig. 1 
 
A
 
).
This is consistent with the predicted size of the protein
backbone (
 
M
 
r
 
 24,747) and variable glycosylation of the
seven potential NH
 
2
 
-linked glycosylation sites. sCD80 mi-
grated slightly faster (
 
M
 
r
 
 30–43,000) under nonreducing
conditions, indicating that the protein does not form disul-
phide-linked multimers, and consistent with the existence
of two predicted disulphide bonds (45).
For valid affinity and kinetic analysis, it is critical that the
interaction under study is monovalent (32), because in-
creasing the binding valency leads to dramatic (but unpre-
dictable) increases in the strength and stability of an inter-
action. The use of the term affinity is usually restricted to
descriptions of the binding strength of monovalent inter-
actions, whereas avidity is used to describe the binding
strength of multivalent interactions. In the present study,
monovalency was ensured by using a monomeric form of
CD80 (sCD80). To check that sCD80 was indeed mono-
meric in solution, it was analyzed by size-exclusion chro-
matography (Fig. 1 
 
C
 
). sCD80 eluted at 
 
M
 
r
 
 
 
z
 
63,000 when
using globular unglycosylated proteins to calibrate the col-
umn (Fig. 1 
 
C
 
). Although this is slightly higher than might
be expected, sCD80 is heavily glycosylated and probably
asymmetric. Therefore, we compared sCD80 with two
similarly asymmetric glycosylated proteins, namely soluble
rat CD2 (sCD2, M
 
r
 
 26–34,000 on SDS-PAGE [46]) and
soluble rat CD48–CD4 (sCD48–CD4, M
 
r
 
 43–64,000 on
SDS-PAGE [26, 47]), both of which are monomeric (26, 47).
sCD80 eluted after sCD48–CD4 and ahead of sCD2 (Fig.
1 
 
C
 
), consistent with it existing as a monomer in solution.
sCD80 appeared to be folded correctly as it bound to all
four mAbs tested (Table 1) and also bound both CD28 and
CTLA-4 (see below). Accurate estimation of affinity and
kinetic constants requires knowledge of the exact concen-
tration of the soluble ligand, which in turn requires that the
proportion of sCD80 that retains ligand binding activity is
known. All of the sCD80 could not be assumed to be ac-
tive because it had been purified using its oligo-histidine
tag, and this would not discriminate between correctly and
ks konC koff + =
Figure 1. Biochemical analysis of sCD80 and CTLA-4 Ig. (A) sCD80
and CTLA-4 Ig (2.5 mg each) were analyzed by SDS-PAGE on 10%
acrylamide under nonreducing and reducing (1bME) conditions. The
migration positions of the indicated (in kD) molecular mass markers are
shown. (B) Measuring the binding activity of sCD80. Protein A–sepharose
beads coated with CTLA-4 Ig or CD22 Ig were incubated with soluble
sCD80, pelleted, and the supernatant analyzed for the presence of sCD80
by reducing SDS-PAGE on 12% acrylamide, together with sCD80 not
exposed to beads (Control). (C) Analysis of sCD80 by size-exclusion chro-
matography. sCD80 (2.1 mg in 0.5 ml) was run on a SUPERDEX S200
HR10/30 column (Pharmacia) at 0.5 ml/min. The calibration markers
shown (Sigma) were alcohol dehydrogenase (Mr 150,000), BSA (Mr
66,000), and carbonic anhydrase (Mr 29,000). sCD48–CD4 and sCD2 are
described in the text.396 Affinity and Kinetics of CD80 Binding to CD28 and CTLA-4
incorrectly folded forms of sCD80. The activity of sCD80
therefore was estimated directly by depleting the sCD80
with protein A–sepharose beads coated with CTLA-4 Ig
(Fig. 1 B). CTLA-4 Ig beads were able to deplete all the
sCD80 (Fig. 1 B), whereas CD22 Ig beads did not deplete,
indicating that close to 100% of the sCD80 retains CTLA-
4-binding activity.
Expression and Analysis of CD28 Ig and CTLA-4 Ig.
The recombinant CD28 used in the present study (CD28
Ig) was a homodimeric fusion protein incorporating the Fc
portion of human g1 Ig heavy chain (29). We expressed
and purified a similar CTLA-4 Ig fusion protein (see Mate-
rials and Methods). SDS-PAGE under reducing and nonre-
ducing conditions indicated that CTLA-4 Ig was expressed
as a disulphide-linked dimer (Fig. 1 A). For kinetic and af-
finity studies, CTLA-4 Ig and CD28 Ig were immobilized
to a dextran matrix on the sensor surface either indirectly,
via a mAb specific for human IgG1, or by direct covalent
coupling through primary amines (see Materials and Meth-
ods). CD28 and CTLA-4 mAbs (Table 1) bound to both
directly and indirectly coupled forms of CD28 Ig and
CTLA-4 Ig (data not shown). Furthermore, sCD80 bound
with a similar affinity to both directly and indirectly cou-
pled CD28 Ig and CTLA-4 Ig (see below; Table 2), indi-
cating that direct covalent coupling did not substantially
disrupt the native structure of these proteins. All subse-
quent measurements were made using directly coupled
CD28 Ig and CTLA-4 Ig.
Affinity Measurements. Affinity and kinetic measure-
ments were performed at 378C except where otherwise in-
dicated. The affinity of sCD80 binding to CTLA-4 and
CD28 was measured directly by equilibrium binding analy-
sis (Figs. 2 and 3), because this avoids the many potential
pitfalls associated with kinetic measurements (see below;
48–50). Increasing concentrations of sCD80 were injected
over sensor surfaces to which CTLA-4 Ig or CD28 Ig had
been immobilized (Figs. 2 A and 3 A, respectively). It is
noteworthy that at all sCD80 concentrations binding
reached equilibrium very rapidly (95% binding within 20 s;
faster for CD28) and that, in the washout phase after the
injection, bound sCD80 dissociated within 20 s (faster for
CD28). These features are typical of interactions with very
fast binding kinetics. The sCD80 samples were also in-
jected over a control sensor surface (with no protein im-
mobilized) to measure the background response (Figs. 2 A
and 3 A, right). Larger background responses are seen in
Fig. 3 A because a tenfold higher range of sCD80 concen-
trations was injected over CD28 Ig (Figs. 2 and 3, legends).
For each sCD80 concentration the binding response (mea-
sured in arbitrary response units [RU]) at equilibrium was
calculated by subtracting the response seen in the control
flow cell from the response seen in the CTLA-4 (see Fig. 2
B) or CD28 (Fig. 3 B) flow cells. A plot of the binding re-
sponse indicates saturable binding and direct fitting of a
standard Langmuir binding isotherm to the data gave Kd
values of 0.38 and 4.2 mM for sCD80 binding to CTLA-4
and CD28, respectively (Figs. 2 B and 3 B, left). Scatchard
plots of the data gave very similar Kd values (Figs. 2 B and 3
B, right). The mean Kd (6 SD) values from several inde-
pendent determinations are shown in Table 2.
Kinetic Measurements. Measurements of binding kinetics
are prone to error, particularly when the kinetics are very
fast, as in the present study (48–50). One source of error is
that part of the response is a background signal that does
not represent true binding. To correct for this, the response
obtained when sCD80 was injected through a control flow
cell (containing no immobilized protein) was subtracted
before analysis. Figs. 4 A and 5 A show typical responses
obtained after injection of sCD80 through flow cells with
two different levels of CTLA-4 Ig (or CD28 Ig) immobi-
Table 1. mAbs that Bind the Recombinant Proteins Used in
This Study
Protein mAb
sCD80* 2D10, mAb 104, L307, BB-1
CD28 Ig‡ CD28.1, CD28.2, CD28.3, CD28.5, CD28.6, 
CLB–CD28/1, KOLT-2
CTLA-4 Ig§ 7F8, 10A8, 11D4
*2D10 (64) was from Dr. Daniel Olive (Inserm 119, Institut Paoli Cal-
mettes, Marseilles, France). mAb 104 (65) was from Immunotech S.A.
(Marseilles, France). L307 (66) was from Becton Dickinson (San Jose,
CA). BB-1 (67) was from PharMingen (San Diego, CA).
‡CD28.1–CD28.6 (68) were from Dr. Daniel Olive. CLB–CD28/
1(15E8 in [66]) was from Dr. René A. W. van Lier (Netherlands Red
Cross Blood Transfusion Service, Amsterdam, the Netherlands).
KOLT-2 (69) was from Dr. Kimitaka Sagawa (Department of Immu-
nology, Kurume University School of Medicine, Kurume, Japan).
§7F8, 10A8, 11D4 were produced as described (54).
Table 2. Summary of Affinity Constants Measured by
Equilibrium Binding
Binding of
sCD80 to
Immobi-
lization* Temperature Kd (mM)‡
CTLA-4 Ig Direct 378C 0.42 (6 0.06, n 5 3)
Direct 258C 0.26 (6 0.06, n 5 3)
Indirect 258C 0.2 (n 5 1)
CD28 Ig Direct 378C 4.0 (6 0.3, n 5 4)
Direct 258C 2.5 (6 0.4, n 5 2)
Indirect 378C 5.5 (n 5 1)
*Direct immobilization was via primary amines on CTLA-4 Ig or
CD28 Ig (see Materials and Methods). Indirect immobilization was via
a directly coupled mAb that binds the Ig portion of CTLA-4 Ig and
CD28 Ig, as previously described (44).
‡The values shown are the means of n determinations (6 SD for n >3
or 6 range for n 5 2).397 van der Merwe et al.
lized, as well as through a control flow cell. Subtraction of
the control flow cell response from the responses in the
CD28 and CTLA-4 flow cells gives the actual binding re-
sponse shown in Figs. 4 B and 5 B (solid lines), which was
subjected to kinetic analysis. A second potential source of
error is that binding and dissociation are limited by the rate
at which protein is delivered to and removed from the sen-
sor surface. This was addressed by using higher than normal
flow rates (40 or 80 ml/min). These flow rates were judged
to be optimal because halving them had little effect on the
association (injection) or dissociation (washout) phases
when sCD80 was injected over CTLA-4 (see Figs. 4 B and
C) or CD28 (Figs. 5, B and C). It should be noted that
even at very high flow rates, binding may still be limited by
mass-transport within an unstirred layer close to the bind-
ing surface (48, 50). The effects of mass-transport limita-
tions within this unstirred layer can be reduced by decreas-
ing the level of immobilized ligand (see below). A third
source of error is rebinding of protein during the dissocia-
tion (washout) phase, which will lead to underestimation of
the dissociation rate. Rebinding can be decreased by im-
mobilizing lower levels of ligand. This is illustrated in
Figs. 4 C and 5 C, in which sCD80 dissociates more rap-
idly when the level of immobilized CTLA-4 or CD28 is de-
creased. sCD80 dissociated from sensor surfaces with high
and low levels of CTLA-4 with apparent dissociation rate
constants (koff) of 0.24 s21 and 0.43 s21, respectively (see
Fig. 4 C; Table 3). Similarly, sCD80 dissociated from high
and low levels of CD28 with koff values of 1.1 s21 and 1.6
s21, respectively (Fig. 5 C; Table 3). Although it is quite
likely that some sCD80 rebinding is still occurring even at
these lower CD28 Ig and CTLA-4 Ig levels, it proved dif-
ficult to collect data of satisfactory quality when CD28 Ig
and CTLA-4 Ig levels were reduced further. Therefore, we
assume that the actual koff values for dissociation of sCD80
from CTLA-4 and CD28 are at least 0.43 s21 and 1.6 s21,
respectively.
Association rate constants (kon) for binding were esti-
mated by nonlinear curve fitting to data from the injection
phase (Figs. 4 D and 5 D) using koff values obtained from
Figure 2. Measuring the affinity of sCD80 binding to CTLA-4 Ig by
equilibrium binding. (A) A range of sCD80 concentrations (2.65 mM and
nine twofold dilutions thereof) were injected sequentially (solid bar) for 2
min at 10 ml/min through a flow cell (FC) with either CTLA-4 Ig (1,500
RUs) or no protein (Control) immobilized. sCD80 (0.26 mM) bound to a
very similar level (255 and 250 RUs) when injected at the beginning and
end of the experiment (data not shown), indicating that the immobilized
CTLA-4 Ig was stable. (B) The equilibrium responses in the CTLA-4 Ig
(d) and Control (m) FCs at each sCD80 concentration and the differ-
ences between these responses (representing actual binding, j) are plot-
ted. The dotted line represents a nonlinear fit of the Langmuir binding
isotherm to the binding data and yields a Kd of 0.4 mM and a binding
maximum of 774 RUs. A Scatchard plot of the same data is shown on the
right. A linear regression fit yields a Kd of 0.4 mM and a binding maxi-
mum of 750 RUs.
Figure 3. Measuring the affinity of sCD80 binding to CD28 Ig by
equilibrium binding. (A) A range of sCD80 concentrations (26.5 mM and
eight twofold dilutions thereof) were injected sequentially (solid bar) for
30 s at 10 ml/min through a FC with either CD28 Ig (immobilized at a
level of 7800 RUs) or an irrelevant protein (Control) immobilized. sCD80
(0.82 mM) injected at the beginning and end of the experiment bound to
a very similar level (160 and 157 RUs), indicating that the immobilized
CD28 Ig was stable. (B) The equilibrium responses in the CD28 Ig (d)
and Control (m) FCs at each sCD80 concentration and the differences
between these responses (representing actual binding, j) are plotted. The
dotted line represents a nonlinear fit of the Langmuir binding isotherm to
the binding data and yields a Kd of 4.1 mM and a binding maximum of
939 RUs. A Scatchard plot of the same data is shown on the right. A linear
regression fit yields a Kd of 4.3 mM and a binding maximum of 952 RUs.398 Affinity and Kinetics of CD80 Binding to CD28 and CTLA-4
analysis of the corresponding dissociation phase. Reason-
ably good fits were obtained with a simple one-to-one
(Langmuir) binding model (Eq. 1). When CTLA-4 and
CD28 were immobilized at the lower levels, sCD80 bound
with mean kon values of 9.4 3 105 M21s21 and 6.6 3 105
M21s21, respectively (Table 3). Slighty slower kon values
were obtained with higher levels of immobilized CTLA-4
(6.2 3 105 M21s21) and CD28 (4.7 3 105 M21s21) (Table 3).
As discussed above, this is likely to reflect underlying mass-
transport limitations within the unstirred layer, which would
be noticeable at higher levels of immobilized ligand (49,
50). Because it was not possible to eliminate completely the
effect of mass transport limitations, we assume that the
actual  kon values for sCD80 binding to CTLA-4 and CD28
are at least 9.4 3 105 M21s21 and 6.6 3 105 M21s21, re-
spectively.
Kinetic constants for CTLA-4 binding were also esti-
mated independently of the dissociation phase by analyzing
the association phase after injection of different concentra-
tions of sCD80 (see Materials and Methods [43]). Although
less accurate and less stringent than a direct fit of equation 1
(48), this approach is useful for verification since it does not
require prior measurement of the koff, but instead provides
its own independent estimate (see Fig. 4 E). Such an analy-
sis was not possible for the lower affinity CD80–CD28 in-
teraction because it has faster kinetics (compare Figs. 4 D
and 5 D) and requires much higher sample concentrations.
The kon (3.2 3 105 M21s21) and koff (0.2 s21) values mea-
Figure 4. Estimating the kon and koff for sCD80 binding CTLA-4 Ig.
(A) Example of primary data. sCD80 (265 nM) was injected (solid bar) at
40 ml/min through FCs with nothing immobilized (Control) or CTLA-4
immobilized at low (920 RUs) or high (2500 RUs) levels. (B) Effect of
varying the flow rate. sCD80 (265 nM) was injected (solid bar) at 20 (solid
line) or 40 (stippled line) ml/min through FCs with high or low levels of
CTLA-4. Background responses (following injection through a control
FC) have been subtracted. (C) Dissociation of sCD80 from FC with high
(d, s) or low (m, n) levels of CTLA-4 Ig at flow rate of 20 (d, m, j)
or 40 (s, n, h) ml/min. Also shown is the fall in response in the same
period following injection of sCD80 through control FC (j, h). The
data fitted reasonably well to single exponential decay curves (dotted lines),
yielding the following t1/2 values: d, 4.8 s; s, 4.4 s; m, 2.2 s; n, 2.35 s;
j, 0.16 s; h, 0.075 s. (D) Estimating the kon. Equation 1 (see Materials
and Methods) was fitted (solid line) to data (d) from (B) (corresponding to
binding of sCD80 to CTLA-4 [low level] at 40 ml/min), yielding the in-
dicated residuals (j) and kon. (E) Independent estimation of kon and koff by
analysis of binding at different sCD80 concentrations. The rate at which
the binding rate decreases (2ks) during the injection phase was deter-
mined for a range of injected sCD80 concentrations (see Materials and
Methods [43]) using data from Fig. 2 A. A linear regression fit of equation
2 to a plot of ks versus sCD80 concentration yielded the kon and koff values.
Figure 5. Estimating the kon and koff for sCD80 binding CD28 Ig. (A)
Example of primary data. sCD80 (2.65 mM) was injected (solid bar) at 80
ml/min through FCs with nothing immobilized (Control) or CD28 Ig im-
mobilized at low (3400 RUs) or high (6200 RUs) levels. (B) Effect of
varying the flow rate. sCD80 (2.65 mM) was injected (solid bar) at 40 (solid
line) or 80 (stippled line) ml/min through FCs with high or low levels of
CD28 Ig. Background responses (following injection through a control
FC) have been subtracted. (C) Dissociation of sCD80 from FC with high
(d, s) or low (m, n) levels of CD28 Ig at flow rate of 40 (d, m, j) or
80 (s, n, h) ml/min. Also shown is the fall in response in the same pe-
riod following injection of sCD80 through a control FC (j, h). The data
fitted well to single exponential decay curves (dotted lines), yielding the
following t1/2 values: d, 0.93 s; s, 0.84 s; m, 0.69 s; D, 0.64 s; j, 0.075 s;
h, 0.04 s. (D) Obtaining the kon by nonlinear curve fitting. Eq. 1 (see
Materials and Methods) was fitted (solid line) to data (d) from (B) (corre-
sponding to binding of sCD80 to CD28 Ig [low level] at 80 ml/min),
yielding the indicated residuals (j) and kon.399 van der Merwe et al.
sured in this manner for sCD80 binding to CTLA-4 Ig
were only slightly slower than values obtained by the direct
nonlinear curve fitting with similar levels of CTLA-4 (see
Table 2).
The accuracy of the measured rate constants can be fur-
ther assessed by comparing the ratio between the koff and
the kon (which provides a calculated Kd or Kdcalc) with the
Kd measured directly by equilibrium binding (Tables 2 and
3). For both CTLA-4 and CD28, the Kd and Kdcalc were
very similar (Tables 2 and 3), indicating consistency be-
tween the kinetic and equilibrium binding analyses. How-
ever, this internal consistency does not exclude the possi-
bility that the true kon and koff values are both faster than
the measured values. Therefore, the measured kon and koff
values represent lower limits for the true kon and koff.
Comparisons with Other Studies. The affinities measured
in the present study for CD80 binding CD28 (Kd 4 mM)
and CTLA-4 (Kd 0.42 mM) are much lower than previ-
ously reported (8, 29). One possible difference is that these
earlier measurements were made at 238C (8, 29). However,
we found that decreasing the temperature from 378C to
258C increased the affinity less than twofold (Table 2). A
more significant difference is likely to be that the soluble
CD80 Ig used in the earlier studies was not monomeric.
This is supported by the observation that the CD80 Ig fu-
sion protein used in these earlier studies, although mono-
meric on SDS-PAGE (Mr 70,000), eluted at Mr z350,000
by size-exclusion chromatography (29), suggesting the
presence of higher aggregates. Such aggregates could well
account for the much higher affinities previously reported.
However, this explanation does not account for 100- to
200-fold higher avidity observed for soluble CTLA-4 Ig
compared with soluble CD28 Ig (for example see reference
30), a difference much larger than the 10-fold difference in
affinity reported in the present study. This discrepancy is
not due to differences in the recombinant proteins used in
these studies, because we were able to reproduce the large
difference in avidity by injecting CD28 Ig and CTLA4 Ig
over a sensor surface onto which sCD80 had been immo-
bilized (Fig. 6). CTLA-4 Ig injected at 0.1 and 1 mg/ml
bound to higher levels than 100-fold higher concentrations
of CD28 Ig (Fig. 6), indicating a .100-fold higher avidity.
Although it is unclear why the avidity difference between
CTLA-4 Ig and CD28 Ig is so much greater than the affin-
ity difference, these results illustrate a major disadvantage of
using multimeric proteins for comparative binding studies.
A similar affinity constant for the CTLA-4–CD80 inter-
action (Kd 0.21 mM at 258C) has recently been obtained by
SPR using a monomeric form of CTLA-4 (51) in solution
and a CD80 Ig fusion protein (29) covalently immobilized
onto the sensor surface (52). No monomeric form of CD28
was analyzed by Greene et al. (52) but, unexpectedly, an
apparently dimeric form of CD28 (CD28tp) bound the im-
mobilized CD80 Ig with an avidity (Kd 2.1–41 mM at
258C) similar to the affinity that we obtained for mono-
meric sCD80 binding to immobilized CD28 (Kd 2.5 mM at
258C). CD28tp also bound immobilized CD80 Ig with an
Table 3. Summary of Kinetic Measurements
Binding of
sCD80 to
Immobilization
level* kon (3 1025 M21s21) koff (s21) Kdcalc (koff/kon, mM)
CTLA-4 Ig High 6.2 6 1.8§ (n 5 3) 0.24 6 0.03 (n 5 3) 0.3
High (linear regression)‡ 3.4 (n 5 1) 0.2 (n 5 1) 0.63
Low 9.4 6 0.3 (n 5 2) 0.43 6 0.03 (n 5 3) 0.46
CD28 Ig High 4.7 6 0.6 (n 5 4) 1.1 6 0.15 (n 5 3) 2.3
Low 6.6 6 0.8 (n 5 4) 1.6 6 0.1 (n 5 4) 2.4
*CTLA-4 Ig or CD28 Ig were immobilized directly. For CTLA-4 Ig, high and low levels were 2,500 and 900 RUs, respectively. For CD28 Ig, high
and low levels were 6,200 and 3,400 RUs, respectively.
‡Data from Fig. 4 E.
§The values shown are the mean of n determinations (6 SD for n >3 or 6 range for n 5 2).
Figure 6. Comparison of avidity of CD28 Ig and CTLA-4 Ig binding
to immobilized sCD80. CD28 Ig or CTLA-4 Ig were injected at 5 ml/
min (258C) at the indicated concentration for 6–8 min through FC with
either sCD80 (3300 RU) or no protein (Control) immobilized. The re-
sponses seen with injection of the three CTLA4 Ig concentrations
through the Control FC were indistinguishable when superimposed.400 Affinity and Kinetics of CD80 Binding to CD28 and CTLA-4
unusually slow apparent kon (7,000 M21s21). One explana-
tion for this discrepency, which is consistent with the slow
apparent kon, is that only a small proportion of the CD28tp
was active. An alternative explanation is that covalent im-
mobilization of the CD80 Ig alters preferentially its interac-
tion with CD28 but not CTLA-4.
Functional Implications. To understand the functional
implications of the solution affinity and kinetic constants
reported in the present study, it is necessary to extrapolate
these values to interactions between the membrane-teth-
ered forms of these molecules (28, 53). Like CD28, CD2
binds its ligand CD58 in solution with a very low affinity
and rapid binding kinetics (27). Dustin et al. (28) have
shown that the interaction between membrane-tethered
CD2 and CD58 also exhibits rapid binding kinetics. This
suggests that the fast solution-binding kinetics observed be-
tween these molecules is a reflection of rapid binding ki-
netics when they are attached to membrane. Theoretical
considerations (53) suggest that the difference in the affinity
of soluble CD80 for CD28 versus CTLA-4 is likely to be
conserved for membrane-attached forms of these mole-
cules. If correct, this implies that CTLA-4 will engage
z10-fold lower surface densities of CD80 than CD28 be-
cause of its z10 fold higher affinity. Unlike CD28, CTLA-4
is not expressed on resting T cells (4) and, although expres-
sion is induced on T cell activation, CTLA-4 is always
present at a z30- to 50-fold lower surface density than
CD28 (54). Under these circumstances CTLA-4 is unlikely
to compete effectively for CD80 and displace it from
CD28, despite its higher affinity. Instead, both CD28 and
CTLA-4 are likely to engage CD80 when they are ex-
pressed simultaneously. In this regard, it is noteworthy that
inhibitory signals transmitted through CTLA-4 appear to
be dominant over the activation signals transmitted through
CD28 (55, 56).
The affinity constants reported in the present study and
previous studies of CD2 and CD4 suggest that accessory T
cell molecules, including those with signaling functions, have
affinities comparable to or lower than the reported affinities
of TCRs for their specific peptide–MHC ligands (Table 4).
Even more striking are the 10- to 100-fold faster koff values
seen for the CD2–CD58 and CD28–CD80 interactions
compared with TCR/peptide–MHC interactions (Table 4).
While it is possible that future studies will identify TCR/
peptide–MHC interactions with similarly fast koff values,
these results suggest that the accessory molecule interac-
tions are generally more unstable than TCR interactions.
Indeed, the binding of CD4 and CD8 to MHC class II and
MHC class I is likely to stabilize further TCR/peptide–
MHC complexes relative to accessory molecule interac-
tions (57).
These observations suggest that within the contact area
between T cells and APC or target cells (18, 58), TCR/
peptide–MHC complexes will generally be longer lived
than CD28–CD80 or CD2–CD58 complexes. This raises
the question as to whether the rapid binding kinetics of CD2
and CD28 interactions are functionally significant. One
crucial feature of T cell antigen recognition is the capacity
of T cells to detect as few as 10 specific peptide–MHC
ligands on cells (59–61). Furthermore, Valitutti et al. (62)
recently reported that, even when presented with very
low levels of peptide–MHC (z100 complexes per cell), a
substantial proportion of TCRs on the T cell surface
(z18,000) appeared to be ligated in the process of T cell
activation. Two important implications of these results are
the following: (a) many peptide–MHC molecules will need
to diffuse through the zone of contact between a T cell and
an APC for the TCR to encounter specific peptide–MHC
molecules; and (b) each specific peptide–MHC molecule
will need to engage serially many TCRs (62). In turn, this
implies that peptide–MHC and TCR molecules will need
to diffuse rapidly into and out of a stable zone of contact
between the T cells and APC and/or that new contacts will
continually need to be formed between these cells (63). It
seems likely that the very fast binding kinetics of CD2 and
CD28 interactions will facilitate these processes by contrib-
uting to a highly dynamic contact zone between T cells
and APC.
Table 4. Comparison of the Binding Constants for the Interactions of the TCR, CD2, CD4, and CD28 with Their Respective Ligands
Interaction kon (M21s21)k off (s21) Kd* (mM) References
TCR binding peptide–MHC
2B4 TCR–MCC peptide plus I-Ek 900–1,700 0.057–0.09 5–50 (70, 71)
2C TCR–p2C peptide plus Ld 11,000–210,000 0.006–0.026 0.1–0.5 (72, 73)
42.12 TCR–OVA peptide plus Kb 3,100 0.02 7–19 (22)
CD2–CD58 >400,000 >4 9–22 (27)
CD4–MHC class II 22 > 3 (74, 75)
CD28–CD80 >660,000 >1.6 4 Present study
*Kd values shown were obtained by equilibrium binding, but the range of Kd values shown for TCR interactions includes some values calculated
from the koff and kon.401 van der Merwe et al.
Since CD28 and CTLA-4 are clearly signaling mole-
cules, able, like the TCR, to transmit positive and negative
cells to T cells, the very fast koff values reported in the
present study indicate that signaling between cells can be
transmitted by very transient molecular interactions. Be-
cause in the case of the TCR, the nature of the signal (pos-
itive or negative) appears to be highly dependent on the ki-
netics of its interaction (22), it is possible that signaling
through CD28 and CTLA-4 will be similarly sensitive to
binding kinetics. Preliminary data suggest that CTLA-4
binds CD86 with a lower affinity and faster dissociation rate
constant than CD80 (52), which may contribute to the re-
ported functional differences between CD80 and CD86 (6).
In this study, we show that CD28 and CTLA-4 bind
CD80 with far lower affinities than previously reported and
that these low affinities are the result of very fast dissocia-
tion rate constants. These kinetic parameters are similar to
those measured for CD2–ligand interactions but very dif-
ferent to reported values for TCR–ligand interactions. We
propose that the fast binding kinetics of CD28 (and CD2)
serve to optimize T cell antigen recognition by (a) allowing
rapid formation and disruption of contacts between T cells
and APC and (b) facilitating lateral diffusion of TCRs and
peptide–MHC molecules through T cell–APC contact
zones.
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